FY2025 · ended Dec 31, 2025 · Revenue $67.48M, +25.2% YoY · Filed Mar 5, 2026
Kura Oncology, Inc. (KURA) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $67.5 million and a net loss of $278.7 million. Free cash flow was -$70.7 million. As of Jun 30, 2026 it held $519.0 million in cash and investments and $24.5 million in total debt.
Revenue (TTM)
$77.22M
Net income (TTM)
$-296.77M
-50.5% vs year-ago TTM
Operating cash flow (TTM)
$-111.76M
-189.4% vs year-ago TTM
Free cash flow (TTM)
$-117.43M
-195.6% vs year-ago TTM
EPS (TTM)
$-3.36
-48.8% vs year-ago TTM
Dividend per share
None
Shares outstanding
88.33M
+9.4% vs prior year
Net cash
$494.57M
as of Jun 30, 2026
Operating margin
-411.9%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- KURA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1422143
- Former names
- ZETA ACQUISITION CORP III (until Mar 10, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $67.5M | $53.9M | — | — | — |
| Operating income | -$303.6M | -$193.2M | — | — | — |
| Net income | -$278.7M | -$174.0M | -$152.6M | -$135.8M | -$130.5M |
| Diluted EPS | -$3.18 | -$2.02 | -$2.08 | -$2.03 | — |
| Operating cash flow | -$64.1M | $134.3M | -$124.8M | -$110.1M | -$104.6M |
| Free cash flow | -$70.7M | $133.8M | -$125.0M | -$110.7M | -$105.7M |
| Total assets | $738.4M | $760.2M | $448.9M | $456.3M | $534.1M |
| Total liabilities | $564.2M | $346.5M | $51.7M | $36.0M | $27.4M |
| Stockholders' equity | $174.1M | $413.6M | $397.3M | $420.3M | $506.6M |
| Cash and investments | $667.2M | $727.4M | $424.0M | $438.0M | $518.0M |
| Total debt | $20.5M | $16.6M | $17.2M | $14.0M | $6.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Sep 9, 2026 | Sep 9, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 8, 2026 | Sep 8, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2026 | Aug 12, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 29, 2026 | Jul 24, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 4, 2026 | Jun 4, 2026 |
All 806 Kura Oncology, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.